DexCom, Inc. (DXCM)
NASDAQ · Health Care · market cap 28.45B
Share price
$84.76
At the last nightly close
Intrinsic value
$35.33
Range $35.33 – $38.86 — the conservative figure is the low end.
Margin of safety
-58.3%
($35.33 − $84.76) ÷ $84.76
EV / EBIT
n/a
Not ranked: negative ebit.
How these numbers are computed
The valuations are calculated in Python from filed accounts, not written by a language model. Three methods run side by side: earnings power value, which capitalises a normalised operating profit; a free-cash-flow model; and the Graham Number as an asset-side cross-check. The conservative figure above starts from the lower of the first two; the Graham Number never enters it.
The frame gives no credit for growth unless the company has earned it: only a return on invested capital that has beaten the cost of capital year after year earns a growth credit, and that credit is capped. A company that compounds will therefore usually read as expensive against it — that is deliberate. It is a price-discipline floor, not a price target, and it is not a view on what the shares will do.
The EV/EBIT ranking uses the median operating profit of up to fifteen fiscal years — a full cycle — where the free screeners use the last twelve months. When the data cannot support a method, the figure reads n/a rather than a number: a free-cash-flow valuation on a bank, a PEG on erratic earnings, a multiple on a company with no operating profit to speak of.
Fundamentals from SEC EDGAR. Prices, market data and technicals from yfinance. Valuation computed 2026-08-29.
Key metrics
Market position
Annual financials
| Period | Revenue | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|
| 2025-FY | 4.66B | 911.8M | 836.3M | 2.14 | 1.08B |
| 2024-FY | 4.03B | 600.0M | 576.2M | 1.46 | 630.7M |
| 2023-FY | 3.62B | 597.7M | 541.5M | 1.40 | 511.9M |
| 2022-FY | 2.91B | 391.2M | 341.2M | 0.88 | 304.7M |
| 2021-FY | 2.45B | 265.8M | 216.9M | 0.53 | 53.3M |
Filed figures from SEC EDGAR, in the reporting currency.
Next earnings
Recent news
- DexCom DXCM Jumps After Earnings Beat And FDA AI Win - StocksToTradestockstotrade.com
- DexCom (NASDAQ:DXCM) Beats Q1 Earnings Forecasts, But Guidance and Revenue Miss Fuel After-Hours Dropchartmill.com
- DexCom (DXCM) Earnings: Latest Report, Earnings Call & Financialspublic.com
- Dexcom (DXCM) Q2 earnings reportcnbc.com
- DexCom, Inc. (DXCM) Stock Price, News, Quote & History - Yahoo Financefinance.yahoo.com
Headlines link to their source. Sperio does not republish article text.
The figures above are the arithmetic. To see what a board of eight AI agents makes of them — macro, sector, filings, news and a devil's advocate whose only job is to attack the thesis — run the full analysis on DXCM.
Run the board on DXCM10 free analyses · no signup, no card
This page presents computed figures and filed financial data for information only. It is not investment advice, not a recommendation to buy or sell any security, and not a statement about what these shares will do. Sperio is a research tool, not an investment adviser. Figures are derived automatically from public filings and market data and may be incomplete, out of date or wrong. See the Terms & Disclaimer.